Vera Therapeutics Inc
VERA
Company Profile
Business description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact
8000 Marina Boulevard
Suite 120
BrisbaneCA94005
USAT: +1 650 770-0077
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
224
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,153.30 | 6.80 | -0.07% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,592.51 | 7.45 | 0.03% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,760.85 | 986.21 | 1.87% |
| NZX 50 Index | 13,514.73 | 59.20 | -0.44% |
| S&P 500 | 6,873.77 | 76.91 | 1.13% |
| S&P/ASX 200 | 8,829.80 | 6.10 | -0.07% |
| SSE Composite Index | 4,123.91 | 6.97 | 0.17% |